+44 (0) 1223 755950
+1 832 327 7413
Vantictumab
REQUEST MORE INFO
Catalogue No: abx831287
Price:
US$464.00
(Size: 100 µg)
Reviews: 
(0 Publications and Reviews)
(0 Publications and Reviews)
Click on the image to see the image legend
Vantictumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting FZD, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Vantictumab has been used in trials studying the treatment of Solid Tumors, Pancreatic Cancer, and Stage IV Pancreatic Cancer.
Research Articles on FZD
| Target | FZD |
| Clonality | Monoclonal |
| Reactivity | Human |
| Expression | Recombinant |
| Tested Applications | ELISA, WB |
| Host | Human |
| Recommended dilutions | Optimal dilutions/concentrations should be determined by the end user. |
| Conjugation | Unconjugated |
| Isotype | IgG2 Lambda |
| Form | Liquid |
| Purity | > 95% |
| Purification | Purified from cell culture supernatants by Protein A/G chromatography. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Buffer | 0.01 M PBS. pH 7.4. |
| CAS Number | 1345009-45-1 |
| Concentration | Batch-dependent, typically between 0.5-2.0 mg/ml. |
| Availability | Shipped within 7-12 working days. |
| Note | This product is for research use only. Not for human consumption, cosmetic, therapeutic or diagnostic use. |